In a letter to the company, the FDA cited safety and dosage concerns as major factors in their decision.
Thomas Castles
Advertisement
Articles by Thomas Castles
The drug helped patients achieve clinical remission, low disease activity.
Advertisement
Latest Updated Articles
FDA Rejects Lilly's BaricitinibJuly 25th 2017
Advertisement
Advertisement
Trending on Rheumatology Live
1
Sonelokimab Reduces Inflammation, Osteoblastic Activity in Phase 2 Proof-of-Concept axSpA Study
2
Bimekizumab Beats Risankizumab on ACR50 in First IL-17A/F vs IL-23 Head-to-Head
3
Joint Ventures: CAR-T, Early Diagnosis Reshape Scleroderma at EULAR 2026
4
Nipocalimab Demonstrates Proof of Concept for FcRn Blockade for SLE
5